Unknown

Dataset Information

0

Acid-induced aggregation propensity of nivolumab is dependent on the Fc.


ABSTRACT: Nivolumab, an anti-programmed death (PD)1 IgG4 antibody, has shown notable success as a cancer treatment. Here, we report that nivolumab was susceptible to aggregation during manufacturing, particularly in routine purification steps. Our experimental results showed that exposure to low pH caused aggregation of nivolumab, and the Fc was primarily responsible for an acid-induced unfolding phenomenon. To compare the intrinsic propensity of acid-induced aggregation for other IgGs subclasses, tocilizumab (IgG1), panitumumab (IgG2) and atezolizumab (aglyco-IgG1) were also investigated. The accurate pH threshold of acid-induced aggregation for individual IgG Fc subclasses was identified and ranked as: IgG1?

SUBMITTER: Liu B 

PROVIDER: S-EPMC4968106 | biostudies-literature | 2016 Aug-Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications


Nivolumab, an anti-programmed death (PD)1 IgG4 antibody, has shown notable success as a cancer treatment. Here, we report that nivolumab was susceptible to aggregation during manufacturing, particularly in routine purification steps. Our experimental results showed that exposure to low pH caused aggregation of nivolumab, and the Fc was primarily responsible for an acid-induced unfolding phenomenon. To compare the intrinsic propensity of acid-induced aggregation for other IgGs subclasses, tociliz  ...[more]

Similar Datasets

| S-EPMC3256859 | biostudies-literature
| S-EPMC2557143 | biostudies-literature
| S-EPMC7077836 | biostudies-literature
| S-EPMC3917556 | biostudies-literature
| S-EPMC4645975 | biostudies-literature
2012-07-15 | E-GEOD-38155 | biostudies-arrayexpress
| S-EPMC3021659 | biostudies-literature
| S-EPMC11367636 | biostudies-literature
| S-EPMC5434662 | biostudies-literature
| S-EPMC5444867 | biostudies-literature